Vaccines as alternatives to antibiotics for food producing animals, part 1 : challenges and needs by Hoelzer, Karin et al.
Hoelzer et al. Vet Res  (2018) 49:64  
https://doi.org/10.1186/s13567-018-0560-8
REVIEW
Vaccines as alternatives to antibiotics 
for food producing animals. Part 1: challenges 
and needs
Karin Hoelzer1* , Lisa Bielke2, Damer P. Blake3, Eric Cox4, Simon M. Cutting5, Bert Devriendt4, 
Elisabeth Erlacher‑Vindel6, Evy Goossens7, Kemal Karaca8, Stephane Lemiere9, Martin Metzner10, 
Margot Raicek6, Miquel Collell Suriñach11, Nora M. Wong1, Cyril Gay12 and Filip Van Immerseel7
Abstract 
Vaccines and other alternative products can help minimize the need for antibiotics by preventing and controlling 
infectious diseases in animal populations, and are central to the future success of animal agriculture. To assess scien‑
tific advancements related to alternatives to antibiotics and provide actionable strategies to support their develop‑
ment, the United States Department of Agriculture, with support from the World Organisation for Animal Health, 
organized the second International Symposium on Alternatives to Antibiotics. It focused on six key areas: vaccines; 
microbial‑derived products; non‑nutritive phytochemicals; immune‑related products; chemicals, enzymes, and 
innovative drugs; and regulatory pathways to enable the development and licensure of alternatives to antibiotics. 
This article, part of a two‑part series, synthesizes and expands on the expert panel discussions regarding opportuni‑
ties, challenges and needs for the development of vaccines that may reduce the need for use of antibiotics in animals; 
new approaches and potential solutions will be discussed in part 2 of this series. Vaccines are widely used to prevent 
infections in food animals. Various studies have demonstrated that their animal agricultural use can lead to significant 
reductions in antibiotic consumption, making them promising alternatives to antibiotics. To be widely used in food 
producing animals, vaccines have to be safe, effective, easy to use, and cost‑effective. Many current vaccines fall short 
in one or more of these respects. Scientific advancements may allow many of these limitations to be overcome, but 
progress is funding‑dependent. Research will have to be prioritized to ensure scarce public resources are dedicated to 
areas of potentially greatest impact first, and private investments into vaccine development constantly compete with 
other investment opportunities. Although vaccines have the potential to improve animal health, safeguard agricul‑
tural productivity, and reduce antibiotic consumption and resulting resistance risks, targeted research and develop‑
ment investments and concerted efforts by all affected are needed to realize that potential.
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1 Introduction
Antibiotic resistance is a global threat to public health [1–4]. 
Every time an antibiotic is used in any setting, there is a risk 
of selecting for resistant bacterial strains [2, 4–6]. Therefore, 
prudent or judicious antibiotic use is important [7]. In ani‑
mal agricultural production, that means using antibiotics 
only when absolutely necessary to protect the health of the 
animal and/or humans, relying on non‑antibiotic alternatives 
to manage animal health where possible, and making opti‑
mal treatment choices with regard to antibiotic drug selec‑
tion and treatment protocol when antibiotics are needed. 
Alternatives to antibiotics can help minimize the need for 
antibiotics by helping to prevent and control infectious dis‑
eases in animal populations. As such, safe and effective 
alternatives are crucially important to the future success of 
animal health and production. To assess scientific advance‑
ments in the research and development of alternatives to 
antibiotics, highlight promising research results and novel 
technologies, assess challenges associated with their com‑
mercialization and use, and provide actionable strategies to 
support their development, the United States Department of 
Agriculture (USDA), with support from the World Organi‑
sation for Animal Health (OIE), organized the second Inter‑
national Symposium on Alternatives to Antibiotics [8]. The 
symposium focused on six key areas: vaccines; microbial‑
derived products; non‑nutritive phytochemicals; immune‑
related products; chemicals, enzymes, and innovative drugs; 
and regulatory pathways to enable the licensure and develop‑
ment of alternatives to antibiotics [9]. This two‑part manu‑
script synthesizes and expands on the scientific presentations 
and expert panel discussions from the symposium regard‑
ing the use of vaccines as alternatives to antibiotics that can 
reduce the need for antibiotic use in animals. Part 1 synthe‑
sizes and expands on the expert panel discussions regarding 
the opportunities, challenges and needs related to vaccines 
that may reduce the requirement for use of antibiotics in ani‑
mals, while part two focuses on highlighting new approaches 
and potential solutions. Other important factors relevant 
to the effective use of vaccines as alternatives to antibiotics, 
such as educational needs for producers and veterinarians, 
the combination of vaccination strategies with best manage‑
ment and husbandry practices, or behavioral aspects related 
to the adoption of vaccination practices are outside the scope 
of this manuscript and therefore not discussed here.
2  Vaccines as alternatives to antibiotics
Vaccines are promising alternatives to antibiotics.1 In a 
recent multi‑country expert‑ranking of alternatives to the 
use of antimicrobial agents in pig production, vaccines 
were ranked highest for perceived feasibility and among 
the top five alternative approaches with regard to per‑
ceived effectiveness [10]. A quasi‑experimental study of 
farrow‑to‑finish pig farms in Belgium has demonstrated 
the cost‑effectiveness of enhanced biosecurity and vac‑
cinations to reduce antibiotic consumption [11]. Simi‑
larly, the implementation of herd‑specific action plans 
that included improvements in vaccination on pig opera‑
tions in Belgium led to reduced antimicrobial consump‑
tion and improvements in production parameters such as 
mortality rates and daily weight gains [12].
A variety of studies have demonstrated that the use of 
various bacterial as well as viral vaccines in animal popu‑
lations can result in a significant reduction in antibiotic 
consumption [13]. For example, the introduction and 
widespread routine use of a vaccine against Aeromonas 
salmonicida led to a significant decrease in antibiotic 
use in the farmed salmon industry [14, 15]. Similarly, 
research has demonstrated that vaccination against Law-
sonia intracellularis, the causative agent of ileitis, in Dan‑
ish pig herds can reduce oxytetracycline consumption for 
this condition by almost 80%; vaccination also led to sig‑
nificantly fewer pigs being treated with oxytetracycline, 
and improved productivity parameters such as aver‑
age daily gains and carcass weights [16]. Improvements 
in mortality rates, feed conversion ratio, pig uniform‑
ity, the occurrence of clinical diarrhea, and the need for 
antibiotic treatment after L. intracellularis vaccination 
have also been reported, albeit the effects were in some 
cases relatively modest and statistical significance was 
not assessed in all of the studies [17–19]. Notably, in one 
study on 64 farms in 9 European countries, the majority 
of pig operations experienced cost reductions for antibi‑
otic treatments after L. intracellularis vaccination, even 
though not all farms were able to reduce their antibiotic 
use [18].
In a study in Austrian pig herds, vaccination against 
porcine circovirus type 2 (PCV‑2), a viral infection which 
leads to generalized immune suppression and therefore 
predisposes animals to secondary bacterial infections, 
led to a statistically significant decrease in antimicrobial 
consumption at the farm level, even though the impact 
varied significantly among farm types; while the impact 
on finishing farms was statistically significant the decline 
was negligible on farrow‑to‑finish farms [20]. The intro‑
duction of PCV‑2 vaccination on a Dutch 460 sow farm 
resulted in improvements in average daily gain, mortality 
rates and decreased antibiotic use (measured as defined 
daily doses), assessed based on data spanning 8 months 
before vaccination, a 4  month transition period, and 
12  months of routine vaccination [21]. Similarly, intro‑
duction of PCV‑2 vaccination in a Canadian pig produc‑
tion system led to statistically significant improvements 
1 Alternatives to antibiotics, in this context, are new options and alternative 
strategies for the prevention and treatment of animal diseases that reduce 
the use of medically important antibiotics, including those deemed critically 
important for human health, in animal agricultural production.
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in attrition, average daily gains and mortality rates, lead‑
ing to a reduction in antibiotic use and an estimated 
return on investment of 6.60 Canadian dollars for each 
dollar invested in vaccines, even though observations 
were restricted to a single operation and six production 
batches before and six after introduction of the vaccine 
[22]. In a Danish wean‑to‑finish pig herd, vaccination 
against both PCV‑2 and L. intracellularis led to a con‑
siderable reduction in antibiotic consumption, improve‑
ments in average daily gains and mortality, and a 2.5–1 
return on investment ratio [23]. In another study of Dan‑
ish swine herds, the use of a vaccine against Actinobacil-
lus pleuropneumonia resulted in a significant decrease 
in antibiotic consumption compared to non‑vaccinated 
herds [24]. Similarly, vaccination against porcine repro‑
ductive and respiratory syndrome (PRRS) virus on a Bel‑
gian pig farm reduced antibiotic consumption by more 
than 50%, leading to a reduction in antibiotic cost by 
almost 50% [25].
Despite a dearth of quantitative studies, experts also 
generally agree that the use of vaccines has reduced the 
need for antimicrobial use in commercial poultry pro‑
duction [13]. In fact, a multi‑center field trial of an avian 
colibacillosis vaccine in broiler chicken found signifi‑
cant differences in antibiotic consumption between vac‑
cinated and control flocks, with consumption estimates 
averaging 0.5 treatment days for vaccinated and 2  days 
for unvaccinated flocks [26]. Other experimental studies 
have produced similar results [27]. Vaccination of broiler 
chicken may also confer additional benefits. Experimen‑
tal evidence suggests that drug‑sensitive parasite strains 
contained in coccidial vaccines and shed by vaccinated 
birds may aid in the restoration of sensitive parasite pop‑
ulations in the broiler house [28].
However, vaccination has not in all cases been asso‑
ciated with a decrease in antibiotic consumption. For 
instance, in one recent Danish study, pig herds that pur‑
chased vaccines against Mycoplasma hyopneumoniae and 
PCV2 had a significantly higher number of antimicrobial 
prescriptions compared with herds not purchasing these 
vaccines [29]. Similarly, a study of farrow‑to‑finish pig 
herds in Belgium, France, Germany and Sweden detected 
that antimicrobial consumption correlated inversely with 
the number of pathogens targeted with vaccines [30]. 
However, another study, a blinded field trial with two M. 
hyopneumoniae vaccines in Danish pig operations, failed 
to detect a statistically significant relationship between 
vaccination and antibiotic consumption or other relevant 
parameters, such as mortality or growth rates, although 
the prevalence of lung lesions was significantly reduced 
by one of the vaccines [31].
The reasons for the variable relationship between vac‑
cination and antibiotic use in these studies have not 
been fully determined, but reinforce the complexity of 
research on the impact of vaccination on on‑farm antibi‑
otic consumption. One important factor may be potential 
systematic differences between vaccinated and control 
herds or flocks. For instance, a higher incidence of certain 
health problems may be a factor influencing operations’ 
vaccination decisions and therefore serve as a source of 
systematic bias [13]. This may, at least in part, explain the 
higher antibiotic consumption in some vaccinated com‑
pared to control operations, in particular if the vaccine is 
not able to completely control the spread of the disease in 
the population.
3  Properties of current vaccines
Conventional veterinary vaccines include attenuated live 
vaccines and inactivated vaccines [32]. Live attenuated 
vaccines provide protection through a limited infection 
of a live organism which elicits an immune response, and 
may provide mucosal immunity [33–35]. The adaptive 
immune response elicited by live vaccines is composed 
of both humoral and cell‑mediated responses, similar 
to that of a natural infection; this is in contrast to inac‑
tivated vaccines, which primarily stimulate a humoral 
response [34–36]. Inactivated or killed vaccines can be 
efficacious for providing protection against systemic 
infections and disease, but the protection provided by 
these vaccines has limited ability to prevent coloniza‑
tion on mucosal surfaces (e.g., in the intestine, urogenital 
tract, and respiratory tract) which are the most common 
portals of entry for pathogens [37, 38]. Additionally, these 
types of vaccine often depend on adjuvants and typi‑
cally require injection of individual animals, which is not 
always practical. For instance, in the poultry industry in 
most regions of the world such approaches are not feasi‑
ble, mostly due to large flock sizes and difficulties related 
to handling large numbers of birds.
For diseases caused by pathogens with multiple sero‑
types and serogroups, such as influenza or Salmonella, 
effective vaccination can be particularly challenging. For 
example, after vaccination, protection against homolo‑
gous strains of Salmonella is high [39, 40], but often 
less protection is afforded against challenge by a heter‑
ologous serotype [35, 41]. Cross‑serotype protection, in 
particular for minor serovars for which live attenuated 
vaccines are not available, has become one of the primary 
research focuses for Salmonella vaccines. Innovative 
new vaccine strategies are aimed at overcoming some of 
these challenges associated with conventional vaccines; 
they include marker vaccines, which permit distinction 
between naturally infected and vaccinated animals, as 
well as vectored, subunit and genetically engineered vac‑
cines, and DNA vaccines [32].
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Vaccines can be used to prevent or control infections 
in animal populations, or to minimize clinical signs and 
thus production losses after infection [32]. In rare cases, 
vaccines may also contribute to the eradication of a path‑
ogen—as demonstrated for instance by the global eradi‑
cation of rinderpest virus [42]. Conceptually, vaccines 
can reduce the threat of antimicrobial resistance develop‑
ment by preventing infections and thereby reducing the 
need to use antibiotics to treat primary bacterial infec‑
tions or secondary bacterial infections following viral or 
parasitic infections. Moreover, vaccines may allow for 
the use of narrower‑spectrum antibiotics by helping to 
rule out certain pathogens as the cause of a disease, and 
reduce disease pressures in populations by increasing 
herd immunity [43]. Potential vaccine effects on bacte‑
rial population densities and resulting resistance gene 
exchange rates have also been proposed [43].
4  Limitations of current vaccines as alternatives 
to antibiotics
The ideal veterinary vaccine is safe, efficacious, and pro‑
vides robust and durable protection against a broad spec‑
trum of pathogens. At the same time, it must be easily 
administered, often on a large scale, and be cost‑effective. 
However, many currently available veterinary vaccines 
have limitations that reduce their usefulness for prevent‑
ing diseases and decreasing the need for antibiotics. For 
example, contagious bovine pleuropneumonia, caused 
by the bacterium Mycoplasma mycoides, remains an 
economically important disease of cattle in sub‑Saharan 
Africa that often necessitates considerable antibiotic 
use [44]. The currently available live vaccine has lim‑
ited efficacy and duration of immunity, and potentially 
severe side effects [44]. The development of a safer and 
more efficacious vaccine is complicated by a variety of 
factors such as a limited understanding of host–patho‑
gen interactions including basic pathophysiological and 
immunological processes during infection, a suboptimal 
challenge model that complicates data interpretation, 
and the possibility of considerable additional regulatory 
requirements for the licensing of genetically modified live 
vaccines [44].
Although not likely to directly reduce antibiotic 
consumption, the European Commission’s project to 
generate an improved classical swine fever vaccine 
(CSFV‑GODIVA project) also provides useful insights 
into the types of challenges associated with many current 
veterinary vaccines. Specifically, the project developed a 
new modified live classical swine fever marker vaccine 
that overcame many limitations of the previously existing 
vaccines with regard to the ability to distinguish vacci‑
nated from naturally infected animals, the immunogenic‑
ity of the vaccine, and the suitability for oral applications, 
in particular for mass‑scale wildlife vaccination [45]. 
The development of a safe and effective vaccine against 
African swine fever has been similarly complicated by 
various factors such as a limited understanding of the 
immune response to infection, strain‑dependent effects 
of gene deletions on virulence attenuation and protec‑
tion, a dearth of small‑animal and in  vitro models, and 
a complex disease epidemiology. Modified live vaccines 
against this viral disease have various drawbacks, includ‑
ing severe side‑effects and the potential for undetected, 
subclinical infections in vaccinated animals that may 
result in viral shedding and can also lead to recombina‑
tion between field and vaccine strains [46]. The devel‑
opment of African swine fever subunit vaccines, on the 
other hand, has been hampered by suboptimal delivery 
or vector systems that often fail to induce a protective 
immunity [46].
As can be inferred from these examples, a variety of 
challenges are shared broadly across different veterinary 
vaccines. Additional file  1 synthesizes some of these 
general limitations associated with many current veteri‑
nary vaccines, based on an assessment of an OIE ad‑hoc 
Group on Prioritisation of Diseases for which Vaccines 
could Reduce Antimicrobial Use in Animals (see next 
section) and a review of research gap data for more than 
50 infectious diseases of animals produced by expert 
groups and captured in DISCONTOOLS, a database cre‑
ated as part of the Action Plan of the European Technol‑
ogy Platform for Global Animal Health and funded under 
the EU 7th framework program [47].
As shown in Additional file  1, current veterinary vac‑
cines often fall short with regard to efficacy, safety and/
or user‑friendliness. The reasons why veterinary vac‑
cines may have limited efficacy are quite varied. In some 
cases [e.g., Streptococcus suis, swine influenza virus, 
Haemophilus parasuis, Eimeria species (Additional 
file  2)], the vaccine strain may not be a good match for 
the field strain. For instance, the pathogen may be evolv‑
ing quickly and the vaccine may not be updated to con‑
fer protection against current strains [e.g., infectious 
bronchitis virus, porcine reproductive and respiratory 
syndrome virus (PRRSV) (Additional file  2)], or it may 
only protect against a limited subset of strains [e.g., 
PRRSV, Actinobacillus pleuropneumoniae (Additional 
file  2)]. In other cases, protection after vaccination may 
be short‑lived and require frequent booster vaccina‑
tions [e.g., Clostridium perfringens, bovine respiratory 
syncytial virus (Additional file 2 and DISCONTOOLS)]. 
In some cases vaccines do not generate a protective 
immune response at all (e.g., African swine fever virus, 
see DISCONTOOLS). This is most commonly the case 
for inactivated or subunit vaccines. Because these vac‑
cines are not actively replicating in the host cells they 
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tend to only induce humoral immune responses, even 
though cellular immune responses are vitally important 
for effective protection against many pathogens. Vaccine 
efficacy depends on the existence of an intact and prop‑
erly functioning immune system, and administration 
has to be timed correctly to account for the lag period 
required to develop a protective immune response. Elicit‑
ing protective immune responses in young animals tends 
to be particularly challenging because the immune sys‑
tem is still developing, and because maternal antibodies 
can interfere with the development of protective immu‑
nity. Vaccination against diseases that require protective 
immunity in young animals can therefore be particularly 
challenging [e.g., infectious bursal disease virus (Addi‑
tional file 2)]. In addition, many veterinary vaccines effec‑
tively reduce the severity and economic impact of the 
disease, but do not fully prevent infection and shedding 
and therefore do little to reduce disease incidence [e.g., 
M. hyopneumoniae (Additional file  2)]. In some cases, 
vaccination can actually increase the survival time for 
infected animals and therefore enhance opportunities 
for disease transmission. Vaccines are also not avail‑
able for all economically important veterinary diseases, 
including many parasitic infections as well as secondary 
bacterial infections, diseases of “minor species” such as 
bees, and diseases that have been largely eliminated by 
management practices but that are recently increasing 
in incidence [e.g., liver flukes, nematodes, varroa mites, 
omphalitis, airsacculitis, cellulitis (Additional file  2 and 
DISCONTOOLS)].
A variety of safety issues are shared by various cur‑
rent veterinary vaccines. Potentially severe side‑effects 
are a concern for many veterinary vaccines, in particular 
for attenuated‑live vaccines and certain adjuvants, and 
can result in abortions, malformations and deaths (e.g., 
contagious bovine pleuropneumoniae, African horse 
sickness, lumpy skin disease, rift valley fever virus, see 
DISCONTOOLS). Even for vaccines with less dramatic 
side‑effects, such as coccidia vaccines, productivity losses 
can be impactful and discourage routine use. Attenu‑
ated live vaccines can also carry a risk of reversion to 
virulent wild type strains, particularly when the molec‑
ular changes responsible for the attenuation of the vac‑
cine strain have not been well‑characterized (e.g., bovine 
respiratory syncytial virus, African horse sickness virus, 
bluetongue virus, PRRS, see DISCONTOOLS). Simi‑
larly, some live vaccines carry a risk of horizontal and/
or vertical transmission and outbreaks caused by vaccine 
strains have been described (e.g., orf, PRRS, rift valley 
fever, see DISCONTOOLS). Finally, for some diseases 
prior vaccination can actually lead to an exacerbation of 
clinical symptoms after infection (e.g., bovine respiratory 
syncytial virus, Mycoplasma bovis, see DISCONTOOLS). 
The immunological reasons for this exacerbation are gen‑
erally not well understood, but are thought to be due to a 
shift in immune response after vaccination (e.g., towards 
Th2‑type responses).
User‑friendliness issues can further limit the useful‑
ness of current vaccines. For instance, mass vaccination 
through spray, drinking water or bait can significantly 
reduce labor costs, directly deliver vaccines to mucosal 
surfaces, and may be the only feasible strategy in certain 
situations such as widespread vaccination of wildlife res‑
ervoirs. Unfortunately, immunological processes such as 
the development of tolerance after mucosal antigen expo‑
sure (discussed in detail in section below) complicate the 
development of vaccines for mass application and most 
current inactivated, subunit and DNA vaccines require 
administration by injection. The potential for user errors 
can also limit vaccine usefulness, for instance errors in 
vaccination route, dose and frequency of vaccination, 
and in proper vaccine handling. Some vaccines, in par‑
ticular certain attenuated live vaccines, are of limited 
stability, leading to cumbersome cold storage require‑
ments and short shelf life, which can complicate vaccine 
use under field conditions (e.g., foot and mouth disease 
virus, Theileria, see DISCONTOOLS). Vaccine manu‑
facturing quality can also be a challenge, in particular 
with certain autogenous or regional vaccines. In some 
cases, limited diagnostic capabilities can make it difficult 
to verify vaccinated animals have mounted a protective 
immune response, which can hinder both the effective 
use of existing vaccines and the development of new ones 
(e.g., mastitis vaccines, bovine respiratory syncytial virus, 
paratuberculosis). Marker vaccines allow vaccinated ani‑
mals to be distinguished from naturally infected animals, 
a vital distinction for many disease control and eradica‑
tion programs. Unfortunately, marker vaccines are cur‑
rently only available for a subset of animal diseases and 
the development of additional vaccines will likely be com‑
plicated by the need for sensitive and specific diagnostic 
tests that can be used in combination with the marker 
vaccine. Commercial interest in developing vaccines for 
animal diseases is a critically important driver of innova‑
tion, but in reality often remains limited. Reasons include 
the relatively high cost of production for many vaccines, 
the costs and time associated with laborious administra‑
tion protocols, in particular if multiple booster vaccina‑
tions are required, and the limited cost‑effectiveness 
compared to other available control options including 
antibiotics. Regulatory restrictions, for instance related 
to novel vaccine technologies such as genetically modi‑
fied live vaccines, can further limit commercial interest 
in vaccine development.
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5  Investment decision‑making in the research 
and development of veterinary vaccines
The development of veterinary vaccines requires consid‑
erable time and resource investments, which pharma‑
ceutical companies could dedicate to other products that 
may be deemed to generate a higher return on invest‑
ment. Factors considered by the pharmaceutical industry 
in the decision to develop a vaccine go beyond demon‑
stration of efficacy. They include unmet needs of the ani‑
mal agriculture industry, market potential, the probability 
of success and the time to market as well as the emer‑
gence of antibiotic resistance. Because of the substantial 
time required for research, development and regulatory 
approval, these decisions rely on a prediction of the situ‑
ation at the time of and subsequent to expected market 
entry. Uncertainty in these predictions can have a sti‑
fling effect on pharmaceutical research and development 
investments. Importantly, the current and future avail‑
ability of other safe and effective management options 
for the disease, including the availability of antibiotics, 
affects this prediction and therefore also has to be con‑
sidered. In fact, the economic attractiveness of vaccines 
is partially dependent on the cost of alternative disease 
management options, including the cost of antibiotics 
where available, although direct and indirect benefits on 
human health including potential food safety improve‑
ments may also be factored into the consideration.
The development strategy for new vaccines should 
therefore be aimed at meeting the needs of the ani‑
mal production industry and consider issues such as 
the length of and common animal health challenges 
encountered during animal production cycles, although 
public health benefits also should be considered. Com‑
bination vaccines that target multiple pathogens are 
one commonly used strategy to overcome the narrow 
spectrum of most vaccines, which is generally much 
narrower than that of antibiotics. Polyvalent and com‑
bination vaccines therefore may be more attractive 
alternatives and more effective in reducing the need for 
antibiotics than monovalent vaccines. The development 
of new safe and effective adjuvants or the combination 
of vaccines with immune modulators may be a prom‑
ising strategy for overcoming limitations in vaccine 
efficacy, in particular for relatively short‑lived species 
such as poultry. Practical considerations, for instance 
the feasibility of vaccine administration to individual 
animals, also have important strategic implications and 
oral vaccines that lend themselves to mass vaccination 
tend to be particularly appealing to industry—if they 
can be developed successfully. Species‑specific fac‑
tors, such as the innate ability to react to immunologi‑
cal triggers [e.g., lipopolysaccharide (LPS)] have to be 
considered as well. In fact, because of the vast physi‑
ological and immunological differences among animal 
species and existing gaps in basic knowledge, adapt‑
ing vaccines to new species may be challenging and 
resource‑intensive. Vaccines for minor species may 
pose a particular challenge in that regard‑ and “minor” 
species such as sheep and goats may in actuality consti‑
tute very large and important parts of the animal popu‑
lations in some countries. Public–private partnerships 
may be a strategy to incentivize the development of 
vaccines that would otherwise not be a high priority for 
the pharmaceutical industry because they can reduce 
research and development costs, limit the associated 
risks, and allow public and private partners to leverage 
their unique strengths. In fact, European Commission 
funding for the CSFV‑GODIVA project demonstrates 
how public funding can drive the development of safer 
and more effective vaccines, even in  situations such 
as classical swine fever where vaccine use is severely 
restricted by government regulations in the traditional 
major animal health product markets.
Close collaboration between private industry, govern‑
ment, and academia is important to ensure that research 
efforts are complimentary, and that each party’s unique 
strengths will foster progress towards the common goal 
of developing vaccines effective in reducing the need for 
antibiotics; for instance, academic (and in some cases 
government) partners may be best equipped to conduct 
basic research (e.g., on species‑specific differences in 
immune responses) and to develop “companion tech‑
nologies” such as diagnostic tests or adjuvants in an effi‑
cient and cost‑effective manner. These technologies may 
prove critical to the commercialization of a new vaccine, 
but reliable technology transfer strategies and close align‑
ment with the industry will be important to assure their 
proper functioning in conjunction with the newly devel‑
oped vaccine. On the other hand, funding agencies may 
be reluctant to fund the types of large‑scale animal tri‑
als needed to demonstrate vaccine efficacy, and academic 
researchers may have to depend on the pharmaceutical 
industry to conduct these types of studies. Close align‑
ment between academic and industry researchers can 
help here as well—for instance by ensuring initial studies 
by academic institutions are appropriately informing sub‑
sequent larger animal trials, and are ideally designed and 
conducted in ways that allow the data to be used as part 
of regulatory submissions.
Regulatory approval processes also have an important 
impact on the decision whether to invest in the research 
and development of a new vaccine. For instance, phar‑
maceutical companies typically seek to license a given 
product in all of the major animal health markets. 
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Harmonization and streamlining of regulatory approval 
pathways across countries and regions can reduce the 
associated development cost and make the product 
more attractive to investors within and outside of the 
pharmaceutical industry. Regulatory strategies such as 
early consultations with regulatory officials can further 
reduce the overall research and development cost and 
allow for the rapid development of a vaccine to address 
new animal disease challenges. In some situations, addi‑
tional, more flexible regulatory pathways may need to be 
considered to address specific challenges, such as dis‑
ease challenges that are specific to a limited geographic 
region or that require vaccination of certain wildlife 
species.
Lastly, the development of new veterinary vaccines has 
to be considered within the broader context of animal 
health and microbial ecologies. For instance, vaccina‑
tion against one pathogen may have unintended impli‑
cations for the incidence of other pathogens through 
processes such as niche alteration. Similarly, as one dis‑
ease is increasingly controlled by vaccination others 
may become more important to the animal production 
industries and may begin to drive antibiotic consump‑
tion. At the same time, it will be impossible to develop 
efficient vaccines for all animal diseases for which antibi‑
otics are used. Therefore, limited research and develop‑
ment resources have to be targeted to priority diseases to 
ensure maximum impact.
6  Prioritization of diseases for which vaccines can 
reduce antibiotic use
Several OIE Member Countries and organizations have 
requested guidance on the prioritization of investments 
that may reduce the need for antimicrobial use in ani‑
mals, in particular in intensive poultry, pig and fish 
production systems that are projected to expand glob‑
ally. In April 2015, the OIE convened an ad hoc Group 
of relevant experts to provide direction to policy makers 
regarding investments in vaccine research, prioritizing 
diseases and syndromes with highest impact on antimi‑
crobial consumption [48]. In order to identify infections 
where new or improved vaccines would have the maxi‑
mum potential to reduce antibiotic use, a number of key 
questions were considered:
1. What are the most prevalent and important bacterial 
infections in chickens and swine; in which commonly 
farmed fish species is antibiotic use common, and 
which bacterial infections are prevalent in those fish 
species?
2. Which common non-bacterial infections, for 
instance caused by protozoal or viral pathogens, trig-
ger empirical antibiotic treatments in chicken, swine 
and fish and also frequently result in bacterial co-
infections?
3. For each of the identified diseases and syndromes, is 
associated antibiotic use high, medium or low rela-
tive to total antibiotic use in that animal species?
4. For each of the identified diseases and syndromes, 
are vaccines available and what is their effectiveness?
5. What is the potential for new or improved vaccines 
to reduce the need for antibiotic treatment?
With the exception of vaccine design, factors that influ‑
ence the utilisation of a vaccine were considered out of 
scope for the task of this group. Also considered out of 
scope were autogenous vaccines, primarily because of 
their lack of broad applicability across time and space, reg‑
istration variability, and the absence of key efficacy data.
The fundamental difference in spectrum between anti‑
biotics and vaccines presented a key challenge to the iden‑
tification of promising candidates to reduce antibiotic 
consumption. First line antibiotic use in animal produc‑
tion is often empirical, based on clinical symptoms, such as 
diarrhoea or respiratory signs, and guided by experience. In 
contrast, as discussed above, current vaccines tend to have 
a narrow spectrum that is limited to specific pathogens or 
pathogen strains. Significant data gaps further complicated 
the prioritization. For example, at the time of the meeting, 
a current list of all available vaccines globally with market‑
ing authorisation was not available. Comprehensive data 
on antibiotic consumption for the various infections in the 
animal species, and the relative incidence of these infec‑
tions worldwide were also sparse. The prioritization there‑
fore relied on expert opinion to close key data gaps.
The group agreed that effective vaccines for the dis‑
eases listed in Additional file 2 could significantly reduce 
the need to use antibiotics in swine, poultry, and fish 
farming. However, significant scientific and technical 
hurdles exist, and an overarching investment in vaccine 
research could have a significant positive effect, particu‑
larly if it addressed the following four priority areas:
1. Maternal antibody interference.
2. Cross-protection or inclusion of relevant strains in 
vaccine formulations.
3. Occurrence of immunological interference in multi-
valent vaccines.
4. Innovative delivery systems to enable mass vaccina-
tion.
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The report was distributed for consideration to 
research funders and global animal health research 
organizations (e.g. STAR‑IDAZ).2 The group also recom‑
mended that global vaccine research networks be created 
to provide resources and expertise in the development of 
vaccines for these critical diseases [49].
Specific examples of recent scientific progress are pro‑
vided in part 2 of this manuscript.
7  Conclusions
Vaccines are proven strategies for the prevention or con‑
trol of infectious diseases in animal populations. There‑
fore, they are promising alternatives that can reduce the 
need to use antibiotics in food‑producing animals and 
their direct mitigating impact on antibiotic consump‑
tion has been demonstrated in a number of studies, even 
though the relationship between antibiotic use and vac‑
cination is not in all cases clear‑cut. The ideal vaccine is 
safe, effective against a broad range of pathogens, and 
easily adapted to mass‑application. At the same time, it 
is cheap to produce and use, easy to register across key 
jurisdictions, and generates durable protection, ideally 
after a single administration.
Existing vaccines still fall short of these ideals. In fact, 
many current vaccines have a number of shortcomings 
with regard to safety, efficacy and/or user‑friendliness 
that limit their ability to replace antibiotic use. Over‑
coming these challenges will take close collaboration and 
innovative new approaches. Public–private partnerships 
represent one promising governing structure for assuring 
such close collaboration across public and private sectors. 
Investments in basic and applied research are equally 
needed to overcome these challenges, and research needs 
will have to be prioritized to ensure scarce resources will 
be preferentially dedicated to areas of greatest potential 
impact. Research to characterize and quantify the impact 
of vaccination on antibiotic use is equally needed.
Yet, some data demonstrating the ability of vaccines 
to reduce antibiotic consumption are already available. 
Similarly, as highlighted in part two of this two‑part 
manuscript, key research breakthroughs and a number 
of highly promising vaccination approaches are already 
in development. These include new oral vaccines based 
on bacterial spores, live vectors, or new delivery strate‑
gies for inactivated oral vaccines; they also include new 
vaccination strategies in‑ovo, combination vaccines that 
protect against multiple pathogens, the use of recent bio‑
technological advances, and comprehensive approaches 
to manage diseases caused by ubiquitous pathogens.
Therefore, further reductions in the need for antibiotic 
use through the use of new vaccines are all‑but‑certain, 
and investments in research and development of new 
vaccines will be vital for the sustained success of animal 
agricultural production around the world.
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